Healthcare Services

Iron Deficiency Injectable Market Analysis Reflecting Expansion Trends And Industry Performance

June 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Trend Is Expected For The Iron Deficiency Injectable Market From 2026 To 2030?

The iron deficiency injectable market has experienced significant growth in recent years. It is anticipated to expand from $15.22 billion in 2025 to $16.74 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.0%. The expansion observed in prior periods can be attributed to factors such as the elevated prevalence of iron deficiency anemia, the constrained effectiveness of oral iron therapies, a rising number of chronic kidney disease cases, an increase in hospital-based infusion treatments, and the broader clinical acceptance of injectable iron.

The iron deficiency injectable market size is anticipated to undergo substantial growth in the coming years. It is projected to expand to $25.69 billion in 2030, achieving a compound annual growth rate (CAGR) of 11.3%. This projected growth can be attributed to factors such as an expanding geriatric population, the increasing prevalence of cancer and inflammatory bowel disease (IBD), the broadening of homecare infusion services, improved safety profiles of newer drug formulations, and expanding healthcare access in developing economies. Major trends expected during this forecast period include a growing preference for injectable iron over oral therapies, its increased utilization in chronic kidney disease management, the rise of day-care and short-duration infusion protocols, the expansion of generic injectable iron products, and higher adoption rates in oncology and chronic disease treatment.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12907&type=smp

Which Core Factors Are Supporting The Expansion Of The Iron Deficiency Injectable Market?

The increasing prevalence of polycystic ovary syndrome (PCOS) is projected to drive the growth of the iron deficiency injectables market moving forward. PCOS is a common hormonal disorder that affects individuals with ovaries, primarily women of reproductive age. This condition frequently leads to excessive blood loss during menstruation, causing patients to develop anemia, which can be addressed by injectable iron deficiency medications. For instance, in June 2023, the World Health Organization, a US-based specialized health agency, reported that polycystic ovary syndrome (PCOS) globally affects an estimated 8–13% of reproductive-aged women, with 70% remaining undiagnosed. Therefore, the widespread occurrence of polycystic ovary syndrome (PCOS) is significantly boosting the iron deficiency injectables market.

What Segment Types Are Included In The Iron Deficiency Injectable Market Analysis?

The iron deficiency injectable market covered in this report is segmented –

1) By Type: Iron Dextran, Ferric Carboxymaltose

2) By Branded or Generics: Branded, Generics

3) By Application: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Ferric Carboxymaltose: Injectafer, Ferinject

Which Trends Are Expected To Shape The Iron Deficiency Injectable Market?

Leading companies in the iron deficiency injectables market are actively creating novel treatments, such as INJECTAFER, to maintain their market standing. An example of this is the June 2023 introduction of INJECTAFER (ferric carboxymaltose injection) for iron deficiency by Daiichi Sankyo Company, a US-based healthcare firm, and American Regent Inc., a US-based injectables producer, following its approval by the Food And Drug Administration, a US-based government agency. Notably, this marks the inaugural and sole intravenous iron replacement therapy sanctioned by the FDA for adult patients suffering from chronic and progressive heart failure. The efficacy and safety of INJECTAFER were evaluated across over 40 clinical trials that included more than 8,800 participants from different countries. This recent approval further strengthens INJECTAFER’s proven application in various patient populations, including adult and pediatric patients with iron-deficient anemia and heart failure.

Who Are The Companies Shaping The Iron Deficiency Injectable Market Landscape?

Major companies operating in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Fresenius Medical Care, AbbVie Inc., Bayer AG, AstraZeneca Plc, GSK Plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH , Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc.

Access The Complete Iron Deficiency Injectable Market Report:

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Which Region Contributes The Most To The Iron Deficiency Injectable Market?

North America was the largest region in the iron deficiency injectable market in 2025. The regions covered in the iron deficiency injectable market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Iron Deficiency Injectable Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12907&type=smp

Browse Through More Reports Similar to the Global Iron Deficiency Injectable Market 2026, By The Business Research Company

Hemochromatosis Iron Overload Disease Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemochromatosis-iron-overload-disease-treatment-global-market-report

Direct Reduced Iron Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/direct-reduced-iron-global-market-report

Foundries Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/foundries-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795